Loading organizations...

§ Private Profile · San Francisco, CA.
Fintech infrastructure providing white-label digital wallet APIs for merchants, enabling branded customer balances and reducing micro-transaction fees.
Based in San Francisco, California, Ansa provides white-labeled digital wallet infrastructure and payment APIs that enable merchants to create branded virtual balances and closed-loop payment systems. The business-to-business platform allows quick-service restaurants, coffee shops, and digital retailers to process high-frequency micro-transactions efficiently while offsetting high credit card processing fees for smaller purchases. The enterprise has raised $19.4 million in total venture funding to date, which includes a $5.4 million seed round and a $14 million Series A round secured in April 2024 to expand its product and engineering teams. Ansa is backed by lead investors Bain Capital Ventures and Renegade Partners, and it provides its embedded finance technology to corporate customers such as Compass Coffee. The financial technology company was founded in 2022 by former Adyen product manager Sophia Goldberg and former Affirm software engineer JT Cho.
Ansa has raised $24.4M across 3 funding rounds.
Ansa has raised $24.4M in total across 3 funding rounds.
Ansa has raised $24.4M across 3 funding rounds. Most recently, it raised $14.0M Series A in April 2024.
Ansa has raised $24.4M in total across 3 funding rounds.
Ansa's investors include Renegade Partners, Andreessen Horowitz, Jana Messerschmidt, TJ Nahigian, BoxGroup, Buckley Ventures, Byers Capital, Cambrian Ventures, Digital Currency Group, Dragonfly Capital Partners, ENIAC Ventures, Founders' Co-op.
Ansa refers to multiple companies. I assume you mean Ansa Biotechnologies (the well-known enzymatic DNA-synthesis company); if you meant a different “Ansa” (payments platform Ansa.dev or AI consultancy ansa.solutions), tell me which and I’ll adapt the profile. Below is a concise investor-style/company profile of Ansa Biotechnologies.
High-Level Overview
Ansa Biotechnologies is a private biotechnology company commercializing a proprietary enzymatic DNA‑synthesis platform that enables faster, longer and higher‑complexity synthetic DNA than traditional chemical methods, targeting research and therapeutic customers in life sciences and industrial biotech.[1][6] The company sells sequence‑verified, clonal or linear double‑stranded DNA constructs (delivering constructs up to 50 kb and no‑assembly synthesis for certain short complex sequences) and positions itself as a faster, greener alternative for DNA supply in cell & gene therapy, vaccines, synthetic biology, agrigenomics and related areas[3][6]. Demand and commercial activity have grown rapidly since its launch, including enterprise collaborations and guarantee‑style service commitments to accelerate adoption and customer confidence[3][1].
Origin Story
Ansa was founded in 2018 as a spinout from the University of California, Berkeley and is headquartered in Emeryville, California[1][6]. Its technology is built on enzymatic DNA synthesis using terminal deoxynucleotidyl transferase (TdT) and polymerase‑nucleotide conjugate chemistry that lets the company synthesize DNA without the limitations of legacy chemical phosphoramidite methods[1]. Early validation included research partnerships (notably collaboration with Microsoft on DNA data storage research) and investor support that carried through a Series A in 2022 and later financing rounds including a Series B to scale operations and commercial services[1][3]. Initial traction included successful technology demonstrations, partnerships with reagent and biosecurity providers, and rapid customer demand after commercialization[1][5][3].
Core Differentiators
Role in the Broader Tech / Bio Landscape
Quick Take & Future Outlook
If you want, I can: